Activity Information

Assess your rheumatology medical knowledge and enhance your patient care. Learn to recognize clinical presentations of rheumatologic conditions; select appropriate tests in the diagnosis, staging, or follow-up of rheumatologic conditions; recommend appropriate management for rheumatologic conditions.

Registration is complimentary for ACR/ARP members. If you are not a member, consider joining ACR/ARP.

Target Audience

Rheumatologists, primary care providers, and healthcare professionals who care for patients with rheumatic diseases; professionals interested or engaged in rheumatology research.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Recognize clinical presentations of rheumatologic conditions
• Select appropriate tests in the diagnosis, staging, or follow-up of rheumatologic conditions
• Recommend appropriate management for rheumatologic conditions
• Assess risk in rheumatologic conditions
• Illustrate pathophysiology and basic science relevant to the care of patients with rheumatologic conditions

CE & MOC Information

CME

Accreditation Statement

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.

AMA Designation Statement

The American College of Rheumatology designates this Enduring Material activity for a maximum of 20.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

CME credit must be claimed by October 11, 2025, at 11:59 PM ET.

MOC

MOC Recognition Statement: American Board of Internal Medicine (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.

After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal. 

MOC points must be claimed by October 11, 2025, at 11:59 PM ET.

Financial Relationship Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

1. Advisor or review panel member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/research support
6. Speaker/honoraria includes speakers bureau, symposia, and expert witness
7. Independent contractor
8. Executive role and/or ownership Interest
9. Royalties and/or patent beneficiary
10. Intellectual property/patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Private investigator
13. Expert witness
14. Equity interest
15. Other: specify details

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.

CARE Development Group Members

The following CARE Development Group members have no relevant financial relationship(s) with ineligible companies to disclose.

• Joel Hirsh, MD
• Jonathan Cheah, MD
• Alan Erickson, MD
• Rumey Ishizawar, MD
• Deana Lazaro, MD
• Jennifer Medlin, MD
• Abhishek Nandan, MD
• Mathilde Pioro, MD
• Amanda Sammut, MD
• Jennifer Stichman, MD
• Jessica Bloom, MD
• Ethan Craig, MD 
  
• Lisa Davis, MD
• Lee Day, MD 
  
• Anisha Dua, MD
• Sarah Fantus, MD
• David Fernandez, MD 
  
• Alison Gizinski, MD
• Melissa Griffith, MD
• Arundathi Jayatilleke, MD
• Tate Johnson, MD
• Fotios Koumpouras, MD
• Bharat Kumar, MD
• Jean Liew, MD
• Amanda Lusa, MD
• Seema Malkana, DO
• Luc Nguyen, MD 
  
• Alexis Ogdie, MD 
  
• Yevgeniy Popov, MD
• Noelle Rolle, MBBBS 
  
• Kai Sun, MD
• Nicole Walton, DO

The following planning committee members have relevant financial relationship(s) with ineligible companies to disclose.

• Bryant England, MD - Boehringer-Ingelheim²
• Angela Robinson, MD - Pfizer⁵ (children are enrolled in Pfizer COVID vaccine trial as participants) 
• Beth Rubinstein, MD - Amgen¹¹; General Electric Co¹¹; Bristol Myers Squibb¹¹
• Matthew Carroll, MD, FACP, FACR - Boehringer-Ingelheim^1,4; Exagen⁶; Flexion⁶; Gilead^1,4 
• Prateek Gandiga, MD, FACP - Alexion Pharmaceuticals⁷ (site investigator); Kezar Pharmaceuticals⁷ (site investigator) 

Acknowledgement of Commercial Support 

Unrestricted medical educational grant support for this activity has been provided by: AbbVie, Inc. and Bristol-Myers Squibb. 

Educational Activity Policies

See ACR educational activity policies, including the online enduring activity refund policy.